CPC Unveils Groundbreaking Connectors for Efficient Gene Therapy Processing
CPC (Colder Products Company), a prominent player in the connection technology industry and part of Dover Corporation, has made a remarkable advancement in the field of biopharmaceutical processing. On January 29, 2025, the company unveiled its innovative MicroCNX® Nano Series aseptic connectors, specifically designed to enhance closed sterile processing for cell and gene therapy (CGT). This launch emphasizes the shift towards modern, efficient practices in an industry that has relied heavily on outdated methods.
The CGT landscape is evolving rapidly, yet the techniques commonly employed—such as biosafety cabinets and tube welding—are often cumbersome and inefficient. Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical sector, highlighted the limitations of current practices: "Cell and gene therapy is advancing quickly, but the industry relies on older, cumbersome techniques like biosafety cabinets or tube welding for sterile processing."
In contrast, the new MicroCNX Nano connectors offer a much simpler solution. Users can quickly connect the halves of the MicroCNX connectors to create a sterile flow path, significantly improving the efficiency of CGT processing assemblies. This represents a pivotal step forward in streamlining operations for CGT manufacturers.
Conventional CGT processes use 1/8- and 1/16-inch flow paths for effective cell transfer with minimal turbulence. An ongoing issue has been holdup volume—unusable liquid trapped in the tubing due to tube welding that necessitates added sections of tubing on either side of the weld. The MicroCNX Nano Series addresses this issue head-on. Without the requirement for extra tubing, these connectors can be quickly joined even outside of a biosafety cabinet, minimizing risks and optimizing workflows.
Even more impressively, the compact size of the MicroCNX Nano connectors allows them to fit directly into handling devices such as freeze cassettes, essential for CGT product cryopreservation. These connectors can withstand extreme low temperatures down to -190°C, ensuring the health of cells during storage and transit, a critical factor in preserving product viability.
Ostreng asserts that “small-format aseptic connectors are the future of CGT sterile processing.” The MicroCNX Series is designed to facilitate faster and more efficient sterile connections, promoting a paradigm shift in how the industry approaches closed systems.
This release builds on CPC's legacy as a pioneer in the design of the industry’s smallest aseptic connectors, specifically tailored for handling the small fluid volumes typical in CGT.
For more details on the capabilities and versatility of the MicroCNX Series connectors, as well as CPC's broader array of innovative connection solutions, interested parties can visit cpcworldwide.com/micro.
CPC has established itself as a leader in single-use connection technologies vital for the manufacture of biopharmaceuticals, cell therapy, and gene therapy products. Their products seamlessly integrate multiple components including process containers and bioreactors, leading to enhancements in media sterility, production yields, and reduced time-to-market. The well-known AseptiQuik® connectors further exemplify CPC’s commitment to facilitating sterile connections in challenging environments.
Dover Corporation, the parent company of CPC, is a global powerhouse with a rich history and a diversified portfolio that generates over $7 billion annually. Headquartered in Downers Grove, Illinois, Dover aims to leverage innovative solutions across various sectors, ensuring continued growth and customer service excellence. For more information about Dover, visit dovercorporation.com.
Major Breakthrough in Sterile Processing
The CGT landscape is evolving rapidly, yet the techniques commonly employed—such as biosafety cabinets and tube welding—are often cumbersome and inefficient. Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical sector, highlighted the limitations of current practices: "Cell and gene therapy is advancing quickly, but the industry relies on older, cumbersome techniques like biosafety cabinets or tube welding for sterile processing."
In contrast, the new MicroCNX Nano connectors offer a much simpler solution. Users can quickly connect the halves of the MicroCNX connectors to create a sterile flow path, significantly improving the efficiency of CGT processing assemblies. This represents a pivotal step forward in streamlining operations for CGT manufacturers.
Overcoming Traditional Challenges
Conventional CGT processes use 1/8- and 1/16-inch flow paths for effective cell transfer with minimal turbulence. An ongoing issue has been holdup volume—unusable liquid trapped in the tubing due to tube welding that necessitates added sections of tubing on either side of the weld. The MicroCNX Nano Series addresses this issue head-on. Without the requirement for extra tubing, these connectors can be quickly joined even outside of a biosafety cabinet, minimizing risks and optimizing workflows.
Even more impressively, the compact size of the MicroCNX Nano connectors allows them to fit directly into handling devices such as freeze cassettes, essential for CGT product cryopreservation. These connectors can withstand extreme low temperatures down to -190°C, ensuring the health of cells during storage and transit, a critical factor in preserving product viability.
A Vision for the Future
Ostreng asserts that “small-format aseptic connectors are the future of CGT sterile processing.” The MicroCNX Series is designed to facilitate faster and more efficient sterile connections, promoting a paradigm shift in how the industry approaches closed systems.
This release builds on CPC's legacy as a pioneer in the design of the industry’s smallest aseptic connectors, specifically tailored for handling the small fluid volumes typical in CGT.
For more details on the capabilities and versatility of the MicroCNX Series connectors, as well as CPC's broader array of innovative connection solutions, interested parties can visit cpcworldwide.com/micro.
About CPC and Dover
CPC has established itself as a leader in single-use connection technologies vital for the manufacture of biopharmaceuticals, cell therapy, and gene therapy products. Their products seamlessly integrate multiple components including process containers and bioreactors, leading to enhancements in media sterility, production yields, and reduced time-to-market. The well-known AseptiQuik® connectors further exemplify CPC’s commitment to facilitating sterile connections in challenging environments.
Dover Corporation, the parent company of CPC, is a global powerhouse with a rich history and a diversified portfolio that generates over $7 billion annually. Headquartered in Downers Grove, Illinois, Dover aims to leverage innovative solutions across various sectors, ensuring continued growth and customer service excellence. For more information about Dover, visit dovercorporation.com.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.